Biogen agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash, valuing the transaction at approximately $5.6 billion. The all-cash deal provides immediate value to Apellis shareholders and is a strategic bolt-on for Biogen that is likely to move the stock prices of both companies and affect the biotech sector.
Biogen agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash, valuing the transaction at approximately $5.6 billion. The all-cash deal provides immediate value to Apellis shareholders and is a strategic bolt-on for Biogen that is likely to move the stock prices of both companies and affect the biotech sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
